AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. It is set to report its Q3 ...

On Thursday, AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $189.65 which represents a slight increase of $1.77 or 0.94% from the prior close of $187.88. The stock opened at $188.43 ...

AbbVie, a global, research-driven biopharmaceutical company, organized a visit to its R&D facilities—the AbbVie Cambridge ...

Dividend stocks can be valuable investments for retirees who want a consistent stream of income flowing into their portfolio ...

AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 ...

Argent Capital Management LLC reduced its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 96.3% in the 3rd quarter, ...

Half a million people across the UK, of whom I am one, live day in day out with Inflammatory Bowel Disease (IBD). IBD is a ...

AbbVie has entered a collaboration with Gedeon Richter (Richter) to develop new treatments for neuropsychiatric conditions.

Pegasus Park is hosting the upcoming Golden Ticket Pitch Competition, offered by the American Cancer Society’s (ACS) ...

This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...

In the closing of the recent trading day, AbbVie (ABBV) stood at $189.65, denoting a +0.94% change from the preceding trading day.

AbbVie (ABBV) and Gedeon Richter announced a new discovery, co-development and license agreement to advance novel targets for the potential ...